341 related articles for article (PubMed ID: 32359397)
1. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma.
Msaouel P; Malouf GG; Su X; Yao H; Tripathi DN; Soeung M; Gao J; Rao P; Coarfa C; Creighton CJ; Bertocchio JP; Kunnimalaiyaan S; Multani AS; Blando J; He R; Shapiro DD; Perelli L; Srinivasan S; Carbone F; Pilié PG; Karki M; Seervai RNH; Vokshi BH; Lopez-Terrada D; Cheng EH; Tang X; Lu W; Wistuba II; Thompson TC; Davidson I; Giuliani V; Schlacher K; Carugo A; Heffernan TP; Sharma P; Karam JA; Wood CG; Walker CL; Genovese G; Tannir NM
Cancer Cell; 2020 May; 37(5):720-734.e13. PubMed ID: 32359397
[TBL] [Abstract][Full Text] [Related]
2. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.
Wei D; Yang Y; Ricketts CJ; Vocke CD; Ball MW; Sourbier C; Wangsa D; Wangsa D; Guha R; Zhang X; Wilson K; Chen L; Meltzer PS; Ried T; Thomas CJ; Merino MJ; Linehan WM
Genes Chromosomes Cancer; 2020 Aug; 59(8):472-483. PubMed ID: 32259323
[TBL] [Abstract][Full Text] [Related]
3. Renal medullary carcinoma in a young mixed-race man in Japan.
Toriyama A; Izumi H; Tomita S; Nagashima Y; Ueda Y; Aoki Y; Tsujimura A; Yao T; Hino O
Pathol Int; 2019 Apr; 69(4):241-245. PubMed ID: 30843648
[TBL] [Abstract][Full Text] [Related]
4. Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye.
Msaouel P; Walker CL; Genovese G; Tannir NM
Mol Cell Oncol; 2020; 7(5):1777060. PubMed ID: 32944636
[TBL] [Abstract][Full Text] [Related]
5. A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma.
Msaouel P; Tannir NM; Walker CL
Clin Cancer Res; 2018 May; 24(9):2044-2049. PubMed ID: 29440190
[TBL] [Abstract][Full Text] [Related]
6. Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas.
Calderaro J; Masliah-Planchon J; Richer W; Maillot L; Maille P; Mansuy L; Bastien C; de la Taille A; Boussion H; Charpy C; Jourdain A; Bléchet C; Pierron G; Gentien D; Choudat L; Tournigand C; Delattre O; Allory Y; Bourdeaut F
Eur Urol; 2016 Jun; 69(6):1055-61. PubMed ID: 26433572
[TBL] [Abstract][Full Text] [Related]
7. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
Carlo MI; Chaim J; Patil S; Kemel Y; Schram AM; Woo K; Coskey D; Nanjangud GJ; Voss MH; Feldman DR; Hsieh JJ; Hakimi AA; Chen YB; Motzer RJ; Lee CH
Clin Genitourin Cancer; 2017 Dec; 15(6):e987-e994. PubMed ID: 28558987
[TBL] [Abstract][Full Text] [Related]
8. SMARCB1/INI1 inactivation in renal medullary carcinoma.
Calderaro J; Moroch J; Pierron G; Pedeutour F; Grison C; Maillé P; Soyeux P; de la Taille A; Couturier J; Vieillefond A; Rousselet MC; Delattre O; Allory Y
Histopathology; 2012 Sep; 61(3):428-35. PubMed ID: 22686875
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in Renal Medullary Carcinoma.
Su Y; Hong AL
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806102
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma.
Bratslavsky G; Gleicher S; Jacob JM; Sanford TH; Shapiro O; Bourboulia D; Gay LM; Andrea Elvin J; Vergilio JA; Suh J; Ramkissoon S; Severson EA; Killian JK; Schrock AB; Chung JH; Miller VA; Mollapour M; Ross JS
Urol Oncol; 2021 Jun; 39(6):367.e1-367.e5. PubMed ID: 33775530
[TBL] [Abstract][Full Text] [Related]
11. Renal medullary carcinomas depend upon
Hong AL; Tseng YY; Wala JA; Kim WJ; Kynnap BD; Doshi MB; Kugener G; Sandoval GJ; Howard TP; Li J; Yang X; Tillgren M; Ghandi M; Sayeed A; Deasy R; Ward A; McSteen B; Labella KM; Keskula P; Tracy A; Connor C; Clinton CM; Church AJ; Crompton BD; Janeway KA; Van Hare B; Sandak D; Gjoerup O; Bandopadhayay P; Clemons PA; Schreiber SL; Root DE; Gokhale PC; Chi SN; Mullen EA; Roberts CW; Kadoch C; Beroukhim R; Ligon KL; Boehm JS; Hahn WC
Elife; 2019 Mar; 8():. PubMed ID: 30860482
[TBL] [Abstract][Full Text] [Related]
12. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance.
Vokshi BH; Davidson G; Tawanaie Pour Sedehi N; Helleux A; Rippinger M; Haller AR; Gantzer J; Thouvenin J; Baltzinger P; Bouarich R; Manriquez V; Zaidi S; Rao P; Msaouel P; Su X; Lang H; Tricard T; Lindner V; Surdez D; Kurtz JE; Bourdeaut F; Tannir NM; Davidson I; Malouf GG
Nat Commun; 2023 May; 14(1):3034. PubMed ID: 37236926
[TBL] [Abstract][Full Text] [Related]
13. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Chabanon RM; Morel D; Eychenne T; Colmet-Daage L; Bajrami I; Dorvault N; Garrido M; Meisenberg C; Lamb A; Ngo C; Hopkins SR; Roumeliotis TI; Jouny S; Hénon C; Kawai-Kawachi A; Astier C; Konde A; Del Nery E; Massard C; Pettitt SJ; Margueron R; Choudhary JS; Almouzni G; Soria JC; Deutsch E; Downs JA; Lord CJ; Postel-Vinay S
Cancer Res; 2021 Jun; 81(11):2888-2902. PubMed ID: 33888468
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling.
Pal SK; Choueiri TK; Wang K; Khaira D; Karam JA; Van Allen E; Palma NA; Stein MN; Johnson A; Squillace R; Elvin JA; Chmielecki J; Yelensky R; Yakirevich E; Lipson D; Lin DI; Miller VA; Stephens PJ; Ali SM; Ross JS
Eur Urol; 2016 Sep; 70(3):516-21. PubMed ID: 26149668
[TBL] [Abstract][Full Text] [Related]
15. Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases.
Jia L; Carlo MI; Khan H; Nanjangud GJ; Rana S; Cimera R; Zhang Y; Hakimi AA; Verma AK; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE; Gartrell BA; Chen YB
Mod Pathol; 2019 Sep; 32(9):1329-1343. PubMed ID: 30980040
[TBL] [Abstract][Full Text] [Related]
16. A case of renal cell carcinoma unclassified with medullary phenotype without detectable gene deletion.
Tsuzuki S; Kataoka TR; Ito H; Ueshima C; Asai S; Yokoo H; Haga H
Pathol Int; 2019 Dec; 69(12):710-714. PubMed ID: 31617267
[TBL] [Abstract][Full Text] [Related]
17. SHP2-Mediated Inhibition of DNA Repair Contributes to cGAS-STING Activation and Chemotherapeutic Sensitivity in Colon Cancer.
Wei B; Xu L; Guo W; Wang Y; Wu J; Li X; Cai X; Hu J; Wang M; Xu Q; Liu W; Gu Y
Cancer Res; 2021 Jun; 81(12):3215-3228. PubMed ID: 33820798
[TBL] [Abstract][Full Text] [Related]
18. STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway.
Cheradame L; Guerrera IC; Gaston J; Schmitt A; Jung V; Goudin N; Pouillard M; Radosevic-Robin N; Modesti M; Judde JG; Cairo S; Goffin V
Oncogene; 2021 Dec; 40(49):6627-6640. PubMed ID: 34625708
[TBL] [Abstract][Full Text] [Related]
19. Haplotype-resolved germline and somatic alterations in renal medullary carcinomas.
Tan KT; Kim H; Carrot-Zhang J; Zhang Y; Kim WJ; Kugener G; Wala JA; Howard TP; Chi YY; Beroukhim R; Li H; Ha G; Alper SL; Perlman EJ; Mullen EA; Hahn WC; Meyerson M; Hong AL
Genome Med; 2021 Jul; 13(1):114. PubMed ID: 34261517
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of renal medullary carcinoma: potential clinical relevance.
Yang XJ; Sugimura J; Tretiakova MS; Furge K; Zagaja G; Sokoloff M; Pins M; Bergan R; Grignon DJ; Stadler WM; Vogelzang NJ; Teh BT
Cancer; 2004 Mar; 100(5):976-85. PubMed ID: 14983493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
